Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the promising field of biotechnology. It serves as a precedent in biotechnology financing - public investment is allowed to participate in companies based on IP generated by Israel's foremost medical research center - the Hadassah University Hospital ("Hadassah"), which is responsible for hospital-based translational research.
The HBL traded stock, as a unique investment vehicle, provides investment exposure to a select portfolio of 6 biotech companies - all based on inventions developed and owned by Hadassah. The companies operate in the fields of Oncology (Rx and Dx), Regenerative Medicine and Inflammatory Disease.
HBL is a subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property and research and development capabilities generated by Hadassah.